ClinicalTrials.gg
Not yet recruitingNCT07949448Updated Nov 19, 2026

Chimeric Antigen-Receptor-Modified T Cells Targeting B7-H3

A Phase 1 interventional study of iC9-CAR.B7-H3 T cells therapy in Brain Tumor, High Grade Glioma and Glioblastoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,446 studies in Brain Neoplasms with a site in United States — 234 open to participants now, 354 under way, 18 of them phase 3. Brain Neoplasms · United States.

Planned enrollment
523rd of 1,191
36 · median 30
Started
2026
with 54 others
Phase 1
417 of 1,446
52 open now
Primary completion
2029-10
later than 299 of 352 live
Registered
1,445th of 1,446
by date

Among the 1,446 studies in Brain Neoplasms with a site in United States, this one is the 523rd largest by planned enrollment of the 1,191 interventional ones that give a count, is one of 55 that started in 2026, is one of 417 in phase 1, reaches primary completion later than 299 of the 352 other live ones, and was the 1,445th registered.

Brain Neoplasms

2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

234 of the 1,446 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

229 more — sign in →

All 234 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,446 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

LCCC 2534-ATL is an early-stage (Phase 1), single-center clinical study evaluating the safety of CAR T-cell therapy in children and adults with high-grade gliomas (HGGs), which are aggressive brain cancers.

The treatment, called iC9-CAR.B7-H3 T cells, uses modified immune cells designed to recognize and attack cancer cells with a protein called B7-H3. The treatment also includes a safety switch (iC9) designed to help stop the modified cells if serious side effects occur.

Earlier studies of B7-H3-targeted CAR T-cell therapy have shown encouraging safety results, with some patients experiencing tumor shrinkage. This study will further evaluate the safety and tolerability of the treatment in children and adults with high-grade gliomas type brain tumors.

The study will use a 3+3 dose-escalation design to evaluate increasing doses and identify the safest appropriate dose. The results will help determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), which is the dose selected for further study.

Participants who qualify will have blood collected to produce the modified T cells. Three treatment doses will be administered two weeks apart. Additional doses may be given.

Participants will be monitored for 15 years after treatment ends or is discontinued to assess potential long-term side effects related to genetic modification of the cells.

03

Conditions studied

  • Brain Tumor
  • High Grade Glioma
  • Glioblastoma
  • Glioblastoma (GBM)
  • High-grade Astrocytoma NOS
  • High-grade Astrocytoma Not Otherwise Specified (NOS)
  • Diffuse Midline Glioma, H3K27-altered
  • Diffuse Hemispheric Glioma, H3G34-mutant

Keywords

  • cellular therapy
  • pediatric
  • adult
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written /assent and HIPAA authorization, signed by the subject, parent/guardian, or legally authorized representative, after the study information has been explained and understood.
  • Meet the age requirements at consent/assent:

    • Adult cohort: ≥18 years.
    • Pediatric cohort: ≥2 and \<18 years, with a minimum body weight of 10 kg at enrollment.
  • performance status ≥50 (>16 years) or Lansky performance status ≥50 (≤16 years). Participants unable to walk because of paralysis but able to sit upright in a wheelchair will be considered ambulatory for performance assessment.
  • Subjects with newly diagnosed non-pontine DMG may enroll following completion of standard radiotherapy and prior to documented disease progression.
  • Unless otherwise specified, subjects must meet all the following criteria to participate in any phase of the study:
  • Histologically or radiographically diagnosed high-grade glioma, including:

    • Recurrent or progressive pediatric-type diffuse high-grade glioma.
    • Recurrent or progressive adult-type diffuse grade 4 glioma.
    • Diffuse midline glioma (DMG), H3 K27-altered, after completion of standard radiotherapy.

Exclusion criteria

Exclusion Criteria:

  • Subjects have presence of clinical and/or radiographic evidence of impending herniation and/or impending spinal cord compression.
  • Pontine diffuse midline glioma (including diffuse intrinsic pontine glioma [DIPG]).
  • Clinical or radiographic evidence of impending herniation and/or impending spinal cord compression.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Adults (Cohort A)

    Adult participants with High-Grade Glioma.

    Biological: iC9-CAR.B7-H3 T cells therapy

  • Experimental
    Pediatrics (Cohort B):

    Pediatric participants with High-Grade Glioma.

    Biological: iC9-CAR.B7-H3 T cells therapy

Interventions

  • BiologicaliC9-CAR.B7-H3 T cells therapy

    Participants receive increasing doses of genetically modified immune cells (iC9-CAR.B7-H3 T cells) to evaluate safety and determine the recommended dose for future studies.

    Also known as: cellular therapy

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-Related Adverse Events (AEs) in adults (Cohort A).

    Number of Participants Experiencing Treatment-Related Grade ≥3 Adverse Events (AEs) in adults will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 6.0.

    Time frame: Up to 8 weeks

  2. Number of Participants Experiencing Treatment-Related Adverse Events (AEs) in Pediatrics (Cohort B)

    Number of Participants Experiencing Treatment-Related Grade ≥3 Adverse Events (AEs) in pediatric participants will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 6.0.

    Time frame: Up to 8 weeks

  3. Cytokine Release Syndrome in adults (Cohort A)

    Cytokine Release Syndrome (CRS) will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 1 - Mild (Symptomatic Management): Fever ≥38\^ o C, No hypotension, No hypoxia, Grade 2 - Moderate (Moderate Intervention): Fever ≥38\^ o C, Hypotension not requiring vasopressors, Hypoxia requiring low-flow nasal cannula (≤6 L/minute) or blow-by, Grade 3 - Severe (Aggressive Intervention): Fever ≥ 38\^ o C , Hypotension requiring a vasopressor with or without vasopressin, Hypoxia requiring high-flow nasal cannula (\>6 L/minute), facemask, nonrebreather mask, or Venturi mask, Grade 4 - Life-threatening (Life-sustaining intervention): Fever ≥38\^oC, Hypotension requiring multiple vasopressors (excluding vasopressin),Hypoxia requiring positive pressure (e.g. Continuous positive airway pressure, BiPAP, intubation, mechanical ventilation), Grade 5 - Death: Death.

    Time frame: Up to 8 weeks

  4. Cytokine Release Syndrome in adults Pediatrics (Cohort B)

    Cytokine Release Syndrome (CRS) will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 1 - Mild (Symptomatic Management): Fever ≥38\^ o C, No hypotension, No hypoxia, Grade 2 - Moderate (Moderate Intervention): Fever ≥38\^ o C, Hypotension not requiring vasopressors, Hypoxia requiring low-flow nasal cannula (≤6 L/minute) or blow-by, Grade 3 - Severe (Aggressive Intervention): Fever ≥ 38\^ o C , Hypotension requiring a vasopressor with or without vasopressin, Hypoxia requiring high-flow nasal cannula (\>6 L/minute), facemask, nonrebreather mask, or Venturi mask, Grade 4 - Life-threatening (Life-sustaining intervention): Fever ≥38\^oC, Hypotension requiring multiple vasopressors (excluding vasopressin),Hypoxia requiring positive pressure (e.g. Continuous positive airway pressure, BiPAP, intubation, mechanical ventilation), Grade 5 - Death: Death.

    Time frame: Up to 8 weeks

  5. Neurotoxicity in adults (Cohort A)

    Neurotoxicity will be graded according to the Central Nervous System (CNS) Toxicity criteria. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 0: Normal or no change from baseline exam at start of therapy, Grade 1: Mild lethargy and/or irritability or visual, motor, or sensory symptoms without change in neurological exam, Grade 2: Moderate lethargy, disorientation, or psychosis lasting \< 48 hours or mild increase in pre-existing neurological deficit, Grade 3: \>48hours of severe lethargy, but responsive to verbal stimuli or disorientation or psychosis lasting \>48 hours, Grade 4: Coma, unresponsive to verbal stimuli, increasing neurological deficit above grade 3, evidence of herniation, development of uncontrolled seizures, intracerebral hemorrhage.

    Time frame: Up to 8 weeks

  6. Neurotoxicity in Pediatrics (Cohort B)

    Neurotoxicity will be graded according to the Central Nervous System (CNS) Toxicity criteria. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 0: Normal or no change from baseline exam at start of therapy, Grade 1: Mild lethargy and/or irritability or visual, motor, or sensory symptoms without change in neurological exam, Grade 2: Moderate lethargy, disorientation, or psychosis lasting \< 48 hours or mild increase in pre-existing neurological deficit, Grade 3: \>48hours of severe lethargy, but responsive to verbal stimuli or disorientation or psychosis lasting \>48 hours, Grade 4: Coma, unresponsive to verbal stimuli, increasing neurological deficit above grade 3, evidence of herniation, development of uncontrolled seizures, intracerebral hemorrhage.

    Time frame: Up to 8 weeks

  7. Treatment-Induced Adverse Neurological Events (TIAN) in adults (Cohort A)

    Treatment-Induced Adverse Neurological Events (TIAN) will be classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0. Grade ≥3 adverse events (AEs) will be reported. TIAN severity will be assessed using the applicable CTCAE v6.0 criteria.

    Time frame: Up to 8 weeks

  8. Treatment-Induced Adverse Neurological Events (TIAN) in Pediatrics (Cohort B)

    Treatment-Induced Adverse Neurological Events (TIAN) will be classified and graded per protocol-specific criteria; Grade ≥3 adverse events (AEs) will be reported. Grade 1 (mild): Headache with fever \>38°C or mild worsening of pre-existing neurological signs/symptoms causing minor functional deficits, requiring observation or symptomatic management only. Grade 2 (moderate): Moderate neurological examination changes from baseline substantially affecting function (e.g., new/worsening hemiparesis, ataxia limiting walking, or cranial neuropathies limiting eating). Grade 3 (severe): Severe neurological signs/symptoms potentially affecting critical cardiorespiratory functions, or increased intracranial pressure (ICP) \>20 mmHg responsive to intervention. Grade 4 (life-threatening).

    Time frame: Up to 8 weeks

Secondary outcomes

  1. The recommended phase 2 dose (RP2D) in adults (Cohort A)

    The recommended phase 2 dose (RP2D) of iC9-CAR.B7-H3 T cells will be determined using modified 3+3 dose-escalation rules. Tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0, and the American Society for Transplantation and Cellular Therapy (ASTCT) criteria for cytokine release syndrome (CRS). Neurotoxicity will be assessed using the Treatment-Induced Adverse Neurological Events (TIAN) criteria.

    Time frame: Up to 8 weeks

  2. The recommended phase 2 dose (RP2D) in Pediatrics (Cohort B)

    The recommended phase 2 dose (RP2D) of iC9-CAR.B7-H3 T cells will be determined using modified 3+3 dose-escalation rules. Tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0, and the American Society for Transplantation and Cellular Therapy (ASTCT) criteria for cytokine release syndrome (CRS). Neurotoxicity will be assessed using the Treatment-Induced Adverse Neurological Events (TIAN) criteria.

    Time frame: Up to 8 weeks

  3. The disease control rate (DCR) in adults (Cohort A)

    The disease control rate (DCR) is the proportion of subjects who achieve a complete response (CR), partial response (PR), or stable disease (SD), as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).

    Time frame: Up to 2 years

  4. The disease control rate (DCR) in Pediatrics (Cohort B)

    The disease control rate (DCR) is the proportion of subjects who achieve a complete response (CR), partial response (PR), or stable disease (SD), as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).

    Time frame: Up to 2 years

  5. Progression free survival (PFS) in adults (Cohort A)

    Progression free survival (PFS) will be measured from first cell administration to progression (as defined as Progressive Disease as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).

    Time frame: Up to 2 years

  6. Progression free survival (PFS) in Pediatrics (Cohort B)

    Progression free survival (PFS) will be measured from first cell administration to progression as defined as Progressive Disease as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).

    Time frame: Up to 2 years

  7. Overall survival (OS) in adults (Cohort A)

    Overall survival (OS) will be measured from the date of initial diagnosis to date of death for any cause.

    Time frame: Up to 2 years

  8. Overall survival (OS) in Pediatrics (Cohort B)

    Overall survival (OS) will be measured from the date of initial diagnosis to date of death for any cause.

    Time frame: Up to 2 years

  9. Duration of response (DOR) in adults (Cohort A)

    Duration of response (DOR) will be defined as the time from documentation of Partial Response (PR) or better to progressive disease (PD). Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).

    Time frame: Up to 2 years

  10. Duration of response (DOR) in Pediatrics (Cohort B)

    Duration of response (DOR) will be defined as the time from documentation of Partial Response (PR) or better to progressive disease (PD). Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).

    Time frame: Up to 2 years

  11. Feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells in adults (Cohort A)

    To evaluate the feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells. Procurement feasibility will be measured as the proportion of individuals who successfully undergo procurement among those who attempt it. Manufacturing feasibility will be measured as the proportion of successfully procured individuals for whom the cells are successfully manufactured to provide three doses.

    Time frame: Up to 8 weeks

  12. Feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells in Pediatrics (Cohort B)

    To evaluate the feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells. Procurement feasibility will be measured as the proportion of individuals who successfully undergo procurement among those who attempt it. Manufacturing feasibility will be measured as the proportion of successfully procured individuals for whom the cells are successfully manufactured to provide three doses.

    Time frame: Up to 8 weeks

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Oct 2029, 34 months later.

Of 176 non-industry phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 34 months is below that.

Counting every sponsor, half of 204 studies reached it within 54 months; a quarter within 36 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Oct 31, 2029
CompletionEst.
Dec 31, 2044
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949448
Collaborators
UNC Clinical Research Partners (CRP), M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Oct 31, 2029 (estimated)
Completion
Dec 31, 2044 (estimated)
Last update
Nov 19, 2026

Study contacts

Caroline Babinec
Contact
UNCImmunotherapy@med.unc.edu
919-984-0000
Catherine Cheng
Contact
UNCImmunotherapy@med.unc.edu
919-984-0000
David Kram, MD, MCR
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion